论文部分内容阅读
We analyzed the data from 80 extranodal NK/T cell lymphoma(ENKTL),nasal type,stage IIE patients.48 patients have been treated by LOP regimen chemotherapy(CT)(L-Asparaginase; Vincristine ; Dexamethasone)and 32 patients by CHOP regimen(cyclophosghamide,tetrahydropyanyl adriamycin; vincristine,prednisone)before radiotherapy(RT).These patients then received extended-field radiotherapy with the doses of DT = 49-59Gy for 27 to 32 cycles followed by a clinic follow-up about 39 months.The results demonstrated a significant improvement of clinic endpoints when comparing the LOP regimen to the CHOP regimen: 68.75%vs.50.00%for complete responses(CR); 20.83%vs.15.63%for partial responses(PR),2.08%vs.3.12%for stable disease(SD)and 8.34%vs.31.25%for progress of diseases(PD).There were statistical differences in objective response rates(ORR,89.58%for LOP vs.65.63%for CHOP; P = 0.009),3 years of overall survival(OS,87.5%for LOP vs.62.5%for CHOP; P = 0.006)and progression-free survival(PFS,79.1%for LOP vs.50%for CHOP; P = 0.007).The difference in RT doses(DT = 49-54Gy vs.DT = 55-59Gy)did not affect the clinic endpoints.No statistic differences were found in the incidences of peripheral neuritis and gastrointestinal tract between the two groups(P > 0.05).In contrast,the incidence of severe grade 3-4 myelosuppression was significantly higher in the CHOP group than in the LOP group(P < 0.05).Transient and clinically manageable coagulation anomaly was much frequent in the LOP regimen(P < 0.05).Multivariate analysis indicated that the CT regimens is an independent prognostic factor for ORR,3 years OS and PFS.Our results showed that the LOP regimen is safe and much more efficient than the conventional CHOP regimen for ENKTL stage IIE patients.